Test your knowledge on second-line treatment and side-effect management in mHER2+ breast cancer

Which of the following are adverse events associated with trastuzumab deruxtecan in the DESTINY-Breast01 and 03 clinical trials?

Nausea

Interstitial lung disease (ILD)/pneumonitis

Vomiting

All of the above

If a patient experiences asymptomatic grade 1 interstitial lung disease (ILD) associated with trastuzumab deruxtecan (T-DXd), which of the following actions should be taken, according to treatment guidelines?

Permanently discontinue T-DXd

Dose reduce T-DXd

Hold T-DXd and initiate prednisone

Switch from T-DXd to trastuzumab emtansine (T-DM1)

Which of the following actions should be taken for a patient initiating trastuzumab deruxtecan (T-DXd) who has moderate hepatic impairment (>1.5 to 3.0 mg/dL)?

Monitor closely

Immediately reduce T-DXd dose

Do not start T-DXd treatment

Hold T-DXd and check liver function again in 6 weeks

{"name":"Test your knowledge on second-line treatment and side-effect management in mHER2+ breast cancer", "url":"https://www.poll-maker.com/QVUQMYLIX","txt":"Which of the following are adverse events associated with trastuzumab deruxtecan in the DESTINY-Breast01 and 03 clinical trials?, If a patient experiences asymptomatic grade 1 interstitial lung disease (ILD) associated with trastuzumab deruxtecan (T-DXd), which of the following actions should be taken, according to treatment guidelines?, Which of the following actions should be taken for a patient initiating trastuzumab deruxtecan (T-DXd) who has moderate hepatic impairment (>1.5 to 3.0 mg\/dL)?","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}

Tools: Poll Maker | Quiz Maker | Super Surveys